Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine fed versus fasted crossover histamine skin reactivity study in healthy volunteers
2018-000913-19Phase 4Completed
- Sponsor
- Faes Farma
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bilastine in allergic rhinoconjunctivitis (ARC) and chronic urticaria (CU) (2 arms), sponsored by Faes Farma. Primary endpoint: Mean AUC0-24 of percentage reduction from baseline in wheal and flare surface areas. Started Apr 2018; status: completed.
02
Drugs
bilastine
03
Conditions
allergic rhinoconjunctivitis (ARC)chronic urticaria (CU)
Beyond the preview
Go deeper on 2018-000913-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000913-19.